Skip to main content
SpringerLink
Log in

Benign prostatic hypertrophy: ‘cost-benefits’ of surgery greater than that of drug therapy

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Eri LM, Tveter KJ. Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. Drugs Aging 1997 Feb; 10(2): 107–18

    Article  PubMed  CAS  Google Scholar 

  2. Barry MJ, Fowler FJ, O’Leary MP, et al. The measurement committee of the American Urological Association: the American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549–57

    PubMed  CAS  Google Scholar 

  3. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy: immediate and postoperative complications: a cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243–7

    PubMed  CAS  Google Scholar 

  4. Finasteride: good tolerability but modest clinical benefit in BPH. Drug Ther Perspect 1993 Aug 30; 2(4): 1–4

    Google Scholar 

  5. Doxazosin: long-acting α-blocker for hypertension and prostatic hypertrophy. Drug Ther Perspect 1995 Sep 4; 6(5): 5–8

    Google Scholar 

  6. Serenoa repens: a phytotherapeutic agent for benign prostatic hypertrophy. Drug Ther Perspect 1997 Aug 4; 10(3): 1–4

    Google Scholar 

  7. Gee WF, Holtgrewe HL, Albertsen PC, et al. Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J Urol 1995; 154: 205–6

    Article  PubMed  CAS  Google Scholar 

  8. Carson CC, Singla A, Rutledge R. Benign prostatic hyperplasia, impact of medical therapy on TURP: a statewide population-based analysis of 26625 patients [abstract no. 1481]. J Urol 1996; 155: 681A

    Article  Google Scholar 

  9. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46: 631–7

    Article  PubMed  CAS  Google Scholar 

  10. Eri LM, Tveter KJ. α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923–34

    Article  PubMed  CAS  Google Scholar 

  11. Russell DJ, Kaufman Jr RP, Cain MR Medical management of benign prostatic hyperplasia (BPH) versus transurethral prostatectomy: the economic consequences [abstract no. 883]. J Urol 1993; 149: 433A

    Google Scholar 

  12. Lepor H. The role of alpha blockade in the therapy of benign prostatic hyperplasia. In: Lepor H, Lawson RK, editors. Prostate diseases. Philadelphia: WB Saunders, 1993: 170–81

    Google Scholar 

  13. Goluboff ET, Olsson CA. Urologists on a tightrope: coping with a changing economy. J Urol 1994; 151: 1–4

    PubMed  CAS  Google Scholar 

  14. Holtgrewe HL. Economics of benign prostatic hyperplasia. In: Kirby R, editor. Textbook of benign prostatic hyperplasia. Oxford: Isis Medical Media, 1996: 527–36

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benign prostatic hypertrophy: ‘cost-benefits’ of surgery greater than that of drug therapy. Drugs Ther. Perspect 10, 13–16 (1997). https://doi.org/10.2165/00042310-199710110-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199710110-00005

Keywords

Search

Navigation